Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRizzuto, Valeria
dc.contributor.authorKoopmann, Tamara T.
dc.contributor.authorBlanco Alvarez, Adoración
dc.contributor.authorTazón Vega, Bárbara
dc.contributor.authorDíaz de Heredia Rubio, Maria Cristina
dc.contributor.authorMañu Pereira, M Mar
dc.contributor.authorBeneitez Pastor, David
dc.contributor.authorVelasco Puyó, Pablo
dc.contributor.authorIdrizovic, Amira
dc.date.accessioned2021-07-06T12:29:33Z
dc.date.available2021-07-06T12:29:33Z
dc.date.issued2021-02-05
dc.identifier.citationRizzuto V, Koopmann TT, Blanco-Álvarez A, Tazón-Vega B, Idrizovic A, Díaz de Heredia C, et al. Usefulness of NGS for Diagnosis of Dominant Beta-Thalassemia and Unstable Hemoglobinopathies in Five Clinical Cases. Front Physiol. 2021 Feb 5;12:628236.
dc.identifier.issn1664-042X
dc.identifier.urihttps://hdl.handle.net/11351/6126
dc.descriptionNext generation sequencing; Rare anemia disorders; Unstable hemoglobinopathies
dc.description.abstractUnstable hemoglobinopathies (UHs) are rare anemia disorders (RADs) characterized by abnormal hemoglobin (Hb) variants with decreased stability. UHs are therefore easily precipitating, causing hemolysis and, in some cases, leading to dominant beta-thalassemia (dBTHAL). The clinical picture of UHs is highly heterogeneous, inheritance pattern is dominant, instead of recessive as in more prevalent major Hb syndromes, and may occur de novo. Most cases of UHs are not detected by conventional testing, therefore diagnosis requires a high index of suspicion of the treating physician. Here, we highlight the importance of next generation sequencing (NGS) methodologies for the diagnosis of patients with dBTHAL and other less severe UH variants. We present five unrelated clinical cases referred with chronic hemolytic anemia, three of them with severe blood transfusion dependent anemia. Targeted NGS analysis was performed in three cases while whole exome sequencing (WES) analysis was performed in two cases. Five different UH variants were identified correlating with patients’ clinical manifestations. Four variants were related to the beta-globin gene (Hb Bristol—Alesha, Hb Debrousse, Hb Zunyi, and the novel Hb Mokum) meanwhile one case was caused by a mutation in the alpha-globin gene leading to Hb Evans. Inclusion of alpha and beta-globin genes in routine NGS approaches for RADs has to be considered to improve diagnosis’ efficiency of RAD due to UHs. Reducing misdiagnoses and underdiagnoses of UH variants, especially of the severe forms leading to dBTHAL would also facilitate the early start of intensive or curative treatments for these patients.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Physiology;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTalassèmia
dc.subjectHemoglobinopatia
dc.subjectSeqüències d'inserció de l'ADN
dc.subject.meshbeta-Thalassemia
dc.subject.meshHemoglobinopathies
dc.subject.meshSequence Analysis, DNA
dc.titleUsefulness of NGS for Diagnosis of Dominant Beta-Thalassemia and Unstable Hemoglobinopathies in Five Clinical Cases
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fphys.2021.628236
dc.subject.decstalasemia beta
dc.subject.decshemoglobinopatías
dc.subject.decsanálisis de secuencias de ADN
dc.relation.publishversionhttps://doi.org/10.3389/fphys.2021.628236
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rizzuto V] Recerca translacional en càncer en la infància i l’adolescència– Rare Anemia Disorders Research Laboratory, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain. Josep Carreras Leukaemia Research Institute, Badalona, Spain. Department of Medicine, Universitat de Barcelona, Barcelona, Spain. [Koopmann TT] Department of Clinical Genetics, Leiden University Medical Center, ERN-EuroBloodNet Member, Leiden, Netherlands. [Blanco-Álvarez A, Tazón-Vega B] Hematologic Molecular Genetics Unit, Hematology Department, Hospital Universitari Vall d’Hebron, ERN-EuroBloodNet Member, Barcelona, Spain. [Idrizovic A, Mañú-Pereira MDM] Recerca translacional en càncer en la infància i l’adolescència– Rare Anemia Disorders Research Laboratory, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain. [Díaz de Heredia C, Velasco P] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain. [Beneitez D] Unitat de Trastorns dels glòbuls vermells, Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. ERN-EuroBloodNet Member, Barcelona, Spain
dc.identifier.pmid33613322
dc.identifier.wos000619475500001
dc.relation.projectidinfo:eu-repo/grantAgreement/EC/H2020/860436
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record